Original White Feather Rice Intranet
Highlights
A few days ago, according to the official website of the State Food and Drug Administration, Beite Pharmaceutical's empagliflozin tablets were approved for generic Class 4 production and were deemed to have been evaluated. According to data from Minenet, the sales scale of empagliflozin tablets in China's three major terminals and six major markets in 2022 (see the end of this article for details of the statistical scope) has exceeded 500 million yuan. Since the beginning of this year, Beite Pharmaceutical has approved 5 products.
Source: One-click search on Minenet
Empagliflozin tablets is a sodium-glucose cotransporter-2 inhibitor drug, which has the effects of lowering blood sugar, reducing body weight, and reducing the risk of small and large vascular complications in patients with type 2 diabetes, and is mainly used for the treatment of patients with type 2 diabetes.
Sales of empagliflozin tablets in retail pharmacies in China in recent years (unit: 10,000 yuan)
Source: Minenet Grid Bureau Database
The sales scale of empagliflozin tablets in China's three major terminal and six major markets has expanded rapidly in recent years, and has exceeded 500 million yuan in 2022, of which the out-of-hospital market (retail pharmacies: urban physical pharmacies + online pharmacies) will increase by 27.76% year-on-year in 2023 after exceeding 100 million yuan.
According to data from Minenet, 20 companies have production approvals for empagliflozin tablets, among them, Chengdu Beite Pharmaceutical, Sinopharm Rongsheng Pharmaceutical, and Zhejiang Huahai Pharmaceutical were approved on the same day. In addition, 12 companies such as Hunan Jiudian Pharmaceutical, Chengdu Hengrui Pharmaceutical, and Shandong Xinhua Pharmaceutical are under review for imitation 4 types of production, and they will be deemed to have passed the evaluation after approval.
Since the beginning of this year, Beite Pharmaceutical has approved products
Source: Minenet China Declaration Progress (MED) database
Since the beginning of this year, Beite Pharmaceutical has approved 5 products, of which empagliflozin tablets and dapagliflozin tablets are diabetes drugs. Dapagliflozin tablets will be a blockbuster variety of 4 billion yuan in China's three major terminal and six major markets in 2022, and it is also the TOP1 product of oral diabetes drugs.
Source: official website of the State Food and Drug Administration, Minenet database
Note: The statistical scope of "China's Three Terminals and Six Major Markets" is as follows: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; If there is any omission, please correct it!